![Bastiaan van der Baan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bastiaan van der Baan
Plus aucun poste en cours
Fortune : 49 280 $ au 31/07/2026
Profil
Bastiaan van der Baan is the founder of thromboDx BV, founded in 2011.
Mr. van der Baan is also the founder of Oncosence BV,Qameleon Therapeutics BV..
Mr. van der Baan is an Independent Director at Tethis SpA since 2021.
Mr. van der Baan is a Venture Partner at Xgen Venture Sgr SpA since 2023.
Mr. van der Baan is Chief Scientific Officer at Nomad Power Solutions, Inc. since 2022.
Mr. van der Baan was President, Director & Chief Scientific Officer at Lixte Biotechnology Holdings, Inc. in 2025.
Mr. van der Baan was Sales Manager at Unilever Plc from 1997 to 2002.
Mr. van der Baan was Chief Clinical & Business Development Officer at Agendia NV from 2013 to 2023.
Mr. van der Baan was Chief Clinical & Business Development Officer at Agendia, Inc. from 2012 to 2023.
Mr. van der Baan graduated from Wageningen University in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,06 % | 06/07/2026 | 11 000 ( 0,06 % ) | 49 280 $ | 31/07/2026 |
Postes actifs de Bastiaan van der Baan
| Sociétés | Poste | Début |
|---|---|---|
Tethis SpA
 Tethis SpA BiotechnologyHealth Technology Develops liquid biopsy platforms and AI-assisted diagnostic solutions for cancer detection and precision medicine | Directeur/Membre du Conseil | 19/07/2021 |
Xgen Venture Sgr SpA
 Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 01/01/2023 |
Anciens postes connus de Bastiaan van der Baan
| Sociétés | Poste | Fin |
|---|---|---|
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Provides genomics technologies for clinical management of cancer | Corporate Officer/Principal | 01/07/2023 |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Operates gene expression analysis-based diagnostics company which development and commercialization of diagnostic tests using tumor gene expression profiling | Corporate Officer/Principal | 01/07/2023 |
thromboDx BV | Fondateur | 01/01/2016 |
| UNILEVER PLC | Sales & Marketing | 01/01/2002 |
Qameleon Therapeutics BV | Fondateur | - |
Formation de Bastiaan van der Baan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Unilever Plc
 Unilever Plc Household/Personal CareConsumer Non-Durables Provides fast moving consumer goods | Consumer Non-Durables |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Operates gene expression analysis-based diagnostics company which development and commercialization of diagnostic tests using tumor gene expression profiling | Health Services |
Lixte Biotechnology Holdings, Inc.
 Lixte Biotechnology Holdings, Inc. BiotechnologyHealth Technology Develops diagnostics, medication and treatments for various forms of cancer | Health Technology |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Provides genomics technologies for clinical management of cancer | Health Technology |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Develops liquid biopsy platforms and AI-assisted diagnostic solutions for cancer detection and precision medicine | Health Technology |
Wageningen University
 Wageningen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
thromboDx BV | |
Oncosence B V
 Oncosence B V Miscellaneous Commercial ServicesCommercial Services Engages in treating cancer by developing senescence inducing and senolytic cell killing compounds | Commercial Services |
Xgen Venture Sgr SpA
Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Finance |
Qameleon Therapeutics BV |
